ERBB2 and gastric cancer: On 15 January 2021, the United States (U.S.)Food and Drug Administration (FDA) approved T-Dxd for adult patients with metastatic GC who have received a prior trastuzumab-based regimen, with the agent representing the second HER2 targeted treatment approved for HER2-positive GC.